uniQure N.V. (QURE) vs Syndax Pharmaceuticals (SNDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Syndax Pharmaceuticals (SNDX) has outperformed uniQure N.V. (QURE) over the past year, gaining 3.5% versus a loss of 60.0%. Over five years, SNDX leads with a -8.4% price change compared with -23.0% for QURE. uniQure N.V. is the larger company by market cap ($1.56 billion vs $1.51 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QURE | SNDX |
|---|---|---|
| Share price | $22.54 | $16.90 |
| Market cap | $1.56B | $1.51B |
| 1-day change | -2.59% | -0.76% |
| YTD return | -3.30% | -18.94% |
| 1-year return | -60.05% | +3.53% |
| 5-year return | -23.02% | -8.39% |
| EPS (TTM) | $-4.03 | $-2.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $71.50 | $25.59 |
| 52-week low | $8.73 | $12.99 |
| Distance from 52-week high | -68.48% | -33.96% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +176.53% | +122.19% |
| Average volume | 1.95M | 1.54M |
| Shares outstanding | 69.37M | 89.30M |
| Employees | 221 | 298 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SNDX has outperformed QURE by 63.6 percentage points over the past year.
About uniQure N.V.
QURE stock →uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 221 employees
About Syndax Pharmaceuticals
SNDX stock →Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 298 employees
QURE vs SNDX FAQ
Which is bigger, uniQure N.V. or Syndax Pharmaceuticals?
uniQure N.V. (QURE) is larger, with a market capitalization of $1.56B compared with $1.51B for Syndax Pharmaceuticals (SNDX).
Which stock has performed better over the past year, QURE or SNDX?
SNDX returned +3.53% over the past 12 months, compared with -60.05% for QURE (price return, excluding dividends). Past performance does not predict future results.
Are uniQure N.V. and Syndax Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.